Even though FDA labels the use of ziprasidone with a warning due to possible mortality in the elderly with dementia related psychosis and potential for QTc prologation, clinical studies showed a small effect of ziprasidone on the QTc interval between __number__ to __number__ ms, no serious electrocardiographic changes, no severe cardiac adverse events, or tardive dyskinesia [ __number__ ].